1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dawnrays Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd.

HHKEX:2348
0.95
HKD
+0.02
(+2.15%)
1.83BMarket Cap
Mar 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.57
0.49
0.61
0.51
0.55
0.6
0.6
0.66
0.78
0.85
0.77
0.7
0.82
- -
Basic EPS, GAAP
0.1
0.13
0.19
0.17
0.18
0.19
0.16
0.17
0.24
0.24
0.22
0.38
0.14
- -
Free Cash Flow per Basic Share
0.09
0.2
0.16
0.18
0.23
0.14
0.11
0.05
-0.01
0.14
0.08
0.03
0.16
- -
Dividend per Share
0.03
0.04
0.05
0.06
0.06
0.13
0.07
0.05
0.1
0.07
0.08
0.07
0.09
- -
Book Value per Share
0.68
0.77
0.92
1.02
1.14
1.21
1.3
1.44
1.59
1.76
1.9
2.21
2.25
2.25
Tangible Book Value per Share
0.64
0.74
0.88
0.98
1.09
1.15
0.99
1.06
1.24
1.4
1.55
1.85
1.91
1.91
Basic Weighted Avg Shares
1,603
1,611
1,608
1,605
1,595
1,586
1,575
1,545
1,498
1,499
1,500
1,505
1,503
1,503
Sales/Revenue/Turnover
915
784
985
824
882
949
950
1,024
1,165
1,278
1,151
1,060
1,231
- -
Operating Margin (%)
25.45
38.53
40.98
42.52
44.76
43.53
33.35
32.82
34.07
35.09
38.42
34.7
24.55
- -
Depreciation Expense
35
46
54
53
53
52
55
60
58
66
84
107
120
- -
Net Income, GAAP
153
205
302
266
293
304
255
268
358
358
326
565
214
- -
Effective Tax Rate (%)
18.98
20.76
19.88
20.22
19.89
19.54
18.7
20.07
19.38
18.83
22.07
11.65
15.43
- -
Profit Margin (%)
16.73
26.17
30.68
32.26
33.2
32.03
26.89
26.18
30.74
28.02
28.32
53.28
17.38
- -
Working Capital
423
583
849
1,042
1,207
1,390
1,096
1,069
814
812
1,051
1,648
1,800
1,800
LT Debt
- -
- -
- -
- -
- -
- -
3
2
2
- -
- -
4
- -
- -
Total Equity
1,092
1,248
1,474
1,637
1,806
1,921
2,026
2,184
2,398
2,650
2,859
3,327
3,385
3,385
Return on Invested Capital (%)
11.52
13.87
18.95
17.6
18
17.57
11.41
11.74
15.92
15.12
11.68
16.75
5.21
- -
Return on Capital (%)
12.36
14.94
20.79
17.01
16.97
16.36
12.47
12.42
15.74
14.2
11.71
17.99
6.37
- -
Return on Common Equity (%)
14.76
17.53
22.2
17.1
17.02
16.31
12.94
12.78
15.74
14.26
11.86
18.29
6.38
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
31
9
77
LT Borrowings
- -
- -
- -
LT Finance Leases
4
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,502
1,503
1,503
Market Capitalization
1,722
1,701
1,648

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,202
2,135
2,294
Cash, Cash Equivalents & STI
1,365
1,400
1,577
Accounts Receivable, Net
122
124
143
Inventories
308
254
215
Total Current Liabilities
555
447
494
Payables & Accruals
- -
- -
- -
ST Debt
31
9
77
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.73%
9.26%
1.75%
Free Cash Flow
-207.32%
-399.43%
429.47%
Net Income, GAAP
2.67%
7.15%
-62.13%
Sales/Revenue/Turnover
2.79%
4.34%
16.09%
Total Cash Common Dividend
15.56%
15.53%
19.52%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,151
2024
- -
- -
1,060
2025
- -
- -
1,231

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.22
2024
- -
- -
0.38
2025
- -
- -
0.14

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.08
2024
- -
- -
0.07
2025
- -
- -
0.09

Company Description

Company Profile APIChatGPT
CEO
Li Wei Yu
Full Time Employees
1,081
Sector
Health technology
Industry
Pharmaceuticals: major
Address
CNT Tower Hong Kong Hong Kong
IPO Date
Jul 11, 2003
Website
en.dawnrays.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dawnrays Pharmaceutical (Holdings) Limited functions as an investment holding enterprise, primarily engaging in the development, manufacturing, and distribution of generic pharmaceutical products across Mainland China and various international markets. The company’s operations are segmented into two key areas: Finished Drugs, which serves as its main source of revenue, and Intermediates and Bulk Medicines. Its product portfolio encompasses a wide array of cephalosporin antibiotics, including pharmaceutical intermediates, bulk active ingredients, injectable powders, and oral antibiotic formulations. Additionally, Dawnrays provides specialized medications addressing conditions related to the cardiovascular system, anti-hepatitis B virus, anti-allergic responses, digestive health, urinary tract issues, and endocrine disorders, available in forms such as tablets, capsules, and granules. A distinguishing feature of the company is its comprehensive vertically integrated approach to cephalosporin antibiotic production. Founded in 1995, the firm’s headquarters are situated in Wan Chai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited operates as a subsidiary of Fortune United Group Limited.